Onconetix, Inc. Selling, General and Administrative Expense
Onconetix, Inc. (ONCO) reported Selling, General and Administrative Expense of $2.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Onconetix, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $2.25M, a 47.39% increase year-over-year.
- Onconetix, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $2.04M, a 21.81% increase year-over-year.
- Onconetix, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $1.50M, a 42.84% decline year-over-year.
- Onconetix, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $2.34M, a 11.38% decline year-over-year.
- Onconetix, Inc. selling, general and administrative expense for fiscal 2025 was $7.04M, a 37.29% decline from fiscal 2024.
- Onconetix, Inc. selling, general and administrative expense for fiscal 2024 was $11.23M, a 23.96% decline from fiscal 2023.
- Onconetix, Inc. selling, general and administrative expense for fiscal 2023 was $14.77M, a 57.95% increase from fiscal 2022.
- Onconetix, Inc. selling, general and administrative expense for fiscal 2022 was $9.35M.
| Period end | Selling, General and Administrative Expense 1 month | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.25M 10-Q · filed 2026-08-13 | $4.28M 10-Q · filed 2026-08-13 | $5.79M derived: sum of 3 quarters · filed 2026-08-13 | $8.13M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $2.04M 10-Q · filed 2026-05-13 | $3.54M derived: sum of 2 quarters · filed 2026-05-13 | $5.89M derived: sum of 3 quarters · filed 2026-05-13 | $7.41M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $3.85M derived: sum of 2 quarters · filed 2026-03-13 | $5.37M derived: sum of 3 quarters · filed 2026-08-13 | $7.04M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $2.34M 10-Q · filed 2025-11-13 | $3.86M derived: sum of 2 quarters · filed 2026-08-13 | $5.54M 10-Q · filed 2025-11-13 | $8.17M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $1.52M 10-Q · filed 2026-08-13 | $3.20M 10-Q · filed 2026-08-13 | $5.83M derived: sum of 3 quarters · filed 2026-08-13 | $8.47M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $1.67M 10-Q · filed 2026-05-13 | $4.31M derived: sum of 2 quarters · filed 2026-05-13 | $6.95M derived: sum of 3 quarters · filed 2026-05-13 | $9.17M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $5.27M derived: sum of 2 quarters · filed 2026-03-13 | $7.50M derived: sum of 3 quarters · filed 2026-03-13 | $11.23M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $2.64M 10-Q · filed 2025-11-13 | $4.86M derived: sum of 2 quarters · filed 2025-11-13 | $8.60M 10-Q · filed 2025-11-13 | $15.03M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $2.22M 10-Q · filed 2025-08-14 | $5.96M 10-Q · filed 2025-08-14 | $12.39M derived: sum of 3 quarters · filed 2025-08-14 | $16.66M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $3.74M 10-Q · filed 2025-06-12 | $10.17M derived: sum of 2 quarters · filed 2025-06-12 | $14.44M derived: sum of 3 quarters · filed 2025-06-12 | $16.74M derived: sum of 4 quarters · filed 2025-06-12 | |||
| 2023-12-31 | $6.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $10.70M derived: sum of 2 quarters · filed 2025-06-02 | $13.00M derived: sum of 3 quarters · filed 2025-06-02 | $14.77M 10-K · filed 2025-06-02 | |||
| 2023-09-30 | $4.27M 10-Q · filed 2024-12-10 | $6.57M derived: sum of 2 quarters · filed 2024-12-10 | $8.34M 10-Q · filed 2024-12-10 | $10.38M derived: sum of 4 quarters · filed 2024-12-10 | |||
| 2023-06-30 | $2.30M 10-Q · filed 2024-08-29 | $79.00K 10-Q · filed 2023-10-20 | $4.07M 10-Q · filed 2024-08-29 | $165.00K 10-Q · filed 2023-10-20 | $6.11M derived: sum of 3 quarters · filed 2024-08-29 | $8.80M derived: sum of 4 quarters · filed 2024-08-29 | |
| 2023-03-31 | $1.77M 10-Q · filed 2024-05-20 | $3.81M derived: sum of 2 quarters · filed 2024-05-20 | $6.50M derived: sum of 3 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $4.73M derived: sum of 2 quarters · filed 2024-04-11 | $9.35M 10-K · filed 2024-04-11 | ||||
| 2022-10-31 | $254.00K 10-K · filed 2024-04-11 | ||||||
| 2022-09-30 | $2.69M 10-Q · filed 2023-11-17 | $7.31M 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |